[Role of radioactive iodine in the treatment of differentiated thyroid cancer: physiopathological basis, results, considerations from the viewpoint of radioprotection].
Postoperative radioiodine treatment of differentiated thyroid cancer occupies a well determined place in the treatment policy of this disease. When the external exposure rate (EER) was determined at 1 m from the patient, 72 h after the administration of the high 131-I dosis, respectively 34 and 56 patients among 80 treated cases presented, and require external help for their daily life (+/- 90% of all cases). This value could be considered as the selective limit in order to authorize them to leave the hospital when favorable socio-economical conditions exist at home.
Département de Radio-Oncologie, l'Institut J. Bordet, Centre des tumeurs de l'Université libre de Bruxelles.
J
J
Frühling
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D002648:Child; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011834:Radiation Monitoring; D011835:Radiation Protection; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*
D007457:Iodine Radioisotopes
Place de l'iode radioactif dans le traitement du cancer thyroïdien différencié: bases physiopathologiques, résultats, considérations du point de vue de la radioprotection.